Stock research
HMTXF Hemostemix Inc
Healthcare • Biotechnology
Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The firm's, ACP-01, lead clinical stage...…
Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The firm's, ACP-01, lead clinical stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. The company was founded by Roger Bergersen and Thomas A. Smeenk in 2006 and is headquartered in Calgary, Canada.
3M change
+0.00%
Range high
$0.05
Congress · 90d
0
Insiders · 90d
0
Public signal layer
Who is disclosing activity in HMTXF?
Price
Showing 3M history. Source: FMP historical price full.
- Prev Close
- $0.05
- Day High
- $0.05
- Day Low
- $0.04
- 52w High
- $0.09
- 52w Low
- $0.04
- Volume
- 6,000
- Avg Volume
- Beta
- 0.619
* TTM/most recent where available
Company
- Ticker
- HMTXF
- Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- CA
- CEO
- Thomas A. Smeenk
- Employees
- 488
- Website
- www.hemostemix.com
Key Metrics
- Market Cap
- 9.22M
- P/E
- P/B
- P/S
- EV/EBITDA
- ROE
- Net Margin
- Div Yield
- FCF/Share
* TTM/most recent where available
DCF Valuation
Standard DCF
Levered DCF
Market Price
DCF vs Price (30D window)
Price uses last 30 days; DCF line holds latest value across the window.DCF line = solid green (latest value repeated across window), Price = dashed blue (daily closes).